Information Provided By:
Fly News Breaks for February 27, 2017
DEPO
Feb 27, 2017 | 07:37 EDT
Janney Capital analyst Ken Trbovich noted that Depomed has filed an amended complaint claiming Purdue willfully violated its patents with its abuse-deterrent formulation of OxyContin. Trbovich continues to think a damage award of $200M or more is possible, "with little to no downside risk" to Depomed, and keeps a Buy rating on the Depomed shares with a $26 fair value estimate.
News For DEPO From the Last 2 Days
There are no results for your query DEPO